Developing as a noteworthy breakthrough in the struggle against obesity, the drug is attracting considerable attention . It combines effects of two recognized GLP-1 receptor agonists, dulaglutide , plus an additional glucose-dependent hormonal component. Preliminary clinical data have indicated substantial body decrease in people with a high BMI ,